Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

OncoCyte share holder equity from 2014 to 2025. Share holder equity can be defined as the sum of preferred and common equity items

OncoCyte Share Holder Equity 2014-2025 | OCX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

OncoCyte share holder equity from 2014 to 2025. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Danaher (DHR)	$133.5B
Elevance Health (ELV)	$96.1B
CVS Health (CVS)	$84.8B
Cencora (COR)	$55.6B
DiDi Global (DIDIY)	$20.3B
Natera (NTRA)	$20B
BioMerieux (BMXMF)	$15.6B
Solventum (SOLV)	$11.5B
ICON (ICLR)	$11.3B
EUROFINS SCIENT (ERFSF)	$11.1B
Revvity (RVTY)	$11B
CochLear (CHEOY)	$10.9B
Avantor (AVTR)	$10.3B
Doximity (DOCS)	$9.9B
Viatris (VTRS)	$9B
Medpace Holdings (MEDP)	$9B
Sonic Healthcare (SKHHY)	$7.7B
HealthEquity (HQY)	$7.3B
Charles River Laboratories (CRL)	$5.2B
Amplifon S.p.A (AMFPF)	$4.3B
Bausch + Lomb (BLCO)	$4.3B
Alignment Healthcare (ALHC)	$3.5B
Sotera Health (SHC)	$3B
BrightSpring Health Services (BTSG)	$2.9B
Organon (OGN)	$2.9B
Surgery Partners (SGRY)	$2.7B
GeneDx Holdings (WGS)	$2.7B
Concentras Parent (CON)	$2.6B
Progyny (PGNY)	$1.8B
Ardent Health Partners (ARDT)	$1.8B